CONTEXT: The full effect of Medicare Part D, after the initial policy transition period and across the United States Medicare population, remains unclear. OBJECTIVE: To estimate nationally representative changes in prescription drug use and out-of-pocket drug costs 2 years after implementation of Part D. DESIGN, SETTING, AND PARTICIPANTS: We examined study outcomes over 8 years (2000 to 2007) and estimated changes after Part D, accounting for earlier trends. Our analyses used the community-dwelling sample of the Medicare Current Beneficiary Survey (unweighted unique n=38,798). Actual post-Part D outcomes were compared with projected values using 2000 to 2005 data. Subgroup analyses and standardization weights were used to address population-level shifts over time in health status and demographic characteristics. MAIN OUTCOME MEASURES: Annual prescription drug fills and out-of-pocket drug costs. RESULTS: We observed significant average per person increases of 1.8 prescription fills [95% confidence interval (CI), 1.1-2.5] in 2006 and 3.4 prescription fills (95% CI, 2.7-4.1) in 2007 above pre-Part D increases of 0.9 prescription fills per year. Average out-of-pocket drug costs decreased significantly by $143 (95% CI, -182.5--103.1) in 2006 and $148 (95% CI, -181.2--114.1) in 2007 above average pre-Part D increases of $12 per year. Prescription fills did not change for beneficiaries with fair to poor health until 2007 when large increases occurred (increases of 3.7 to 11.0 fills above pre-Part D trends). Significant reductions in OOP drug costs occurred in 2006 and persisted into 2007 across all groups except for sick and poor beneficiaries without Medicaid. CONCLUSIONS: After the transition year of 2006, the impact of Part D seemed larger and more consistent across the Medicare population. Of note, sick and poor beneficiaries experienced significant improvements in prescription drug use in 2007.
CONTEXT: The full effect of Medicare Part D, after the initial policy transition period and across the United States Medicare population, remains unclear. OBJECTIVE: To estimate nationally representative changes in prescription drug use and out-of-pocket drug costs 2 years after implementation of Part D. DESIGN, SETTING, AND PARTICIPANTS: We examined study outcomes over 8 years (2000 to 2007) and estimated changes after Part D, accounting for earlier trends. Our analyses used the community-dwelling sample of the Medicare Current Beneficiary Survey (unweighted unique n=38,798). Actual post-Part D outcomes were compared with projected values using 2000 to 2005 data. Subgroup analyses and standardization weights were used to address population-level shifts over time in health status and demographic characteristics. MAIN OUTCOME MEASURES: Annual prescription drug fills and out-of-pocket drug costs. RESULTS: We observed significant average per person increases of 1.8 prescription fills [95% confidence interval (CI), 1.1-2.5] in 2006 and 3.4 prescription fills (95% CI, 2.7-4.1) in 2007 above pre-Part D increases of 0.9 prescription fills per year. Average out-of-pocket drug costs decreased significantly by $143 (95% CI, -182.5--103.1) in 2006 and $148 (95% CI, -181.2--114.1) in 2007 above average pre-Part D increases of $12 per year. Prescription fills did not change for beneficiaries with fair to poor health until 2007 when large increases occurred (increases of 3.7 to 11.0 fills above pre-Part D trends). Significant reductions in OOP drug costs occurred in 2006 and persisted into 2007 across all groups except for sick and poor beneficiaries without Medicaid. CONCLUSIONS: After the transition year of 2006, the impact of Part D seemed larger and more consistent across the Medicare population. Of note, sick and poor beneficiaries experienced significant improvements in prescription drug use in 2007.
Authors: John Hsu; Vicki Fung; Mary Price; Jie Huang; Richard Brand; Rita Hui; Bruce Fireman; Joseph P Newhouse Journal: JAMA Date: 2008-04-23 Impact factor: 56.272
Authors: Jeanne M Madden; Amy J Graves; Fang Zhang; Alyce S Adams; Becky A Briesacher; Dennis Ross-Degnan; Jerry H Gurwitz; Marsha Pierre-Jacques; Dana Gelb Safran; Gerald S Adler; Stephen B Soumerai Journal: JAMA Date: 2008-04-23 Impact factor: 56.272
Authors: Jennifer M Polinski; Elaine Kilabuk; Sebastian Schneeweiss; Troyen Brennan; William H Shrank Journal: J Am Geriatr Soc Date: 2010-09 Impact factor: 5.562
Authors: Sebastian Schneeweiss; Amanda R Patrick; Alex Pedan; Laleh Varasteh; Raisa Levin; Nan Liu; William H Shrank Journal: Health Aff (Millwood) Date: 2009-02-03 Impact factor: 6.301
Authors: Wesley Yin; Anirban Basu; James X Zhang; Atonu Rabbani; David O Meltzer; G Caleb Alexander Journal: Ann Intern Med Date: 2008-01-07 Impact factor: 25.391
Authors: Jeanne M Madden; Alyce S Adams; Robert F LeCates; Dennis Ross-Degnan; Fang Zhang; Haiden A Huskamp; Daniel M Gilden; Stephen B Soumerai Journal: JAMA Psychiatry Date: 2015-02 Impact factor: 21.596
Authors: Alyce S Adams; Jeanne M Madden; Fang Zhang; Stephen B Soumerai; Dan Gilden; Jennifer Griggs; Connie M Trinacty; Christine Bishop; Dennis Ross-Degnan Journal: Med Care Date: 2014-08 Impact factor: 2.983
Authors: Becky A Briesacher; Jeanne M Madden; Fang Zhang; Hassan Fouayzi; Dennis Ross-Degnan; Jerry H Gurwitz; Stephen B Soumerai Journal: Ann Intern Med Date: 2015-06-16 Impact factor: 25.391
Authors: Huseyin Naci; Stephen B Soumerai; Dennis Ross-Degnan; Fang Zhang; Becky A Briesacher; Jerry H Gurwitz; Jeanne M Madden Journal: Health Aff (Millwood) Date: 2014-08 Impact factor: 6.301